Aerpio Therapeutics, Inc. Company Profile
Aerpio Therapeutics, Inc. is a clinicalâstage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of Hypoxia-inducible Factor 1α (HIFâ1α). The Companyâs lead program, AKBâ9778, is a firstâinâclass stabilizer of the Tie2 pathway and is in clinical development for diabetic macular edema. AKBâ4924, a HIFâ1α stabilizer, is in late preclinical development for inflammatory bowel disease. More information is available at www.aerpio.com.
News Articles
Aerpio closes $27 million series A financing
Aerpio Therapeutics has closed a $27 million Series A financing. The round was led by Novartis BioVentures and joined by Venture Investors LLC, Triathlon Medical Ventures, Kearny Venture Partners, Ath...
Aerpio raises $27M in series A
Aerpio Therapeutics Inc. (Cincinnati, Ohio) raised $27 million in a series A round led by Novartis BioVentures. Venture Investors; Triathlon Medical Ventures; Kearny Venture Partners; Athenian Venture...
Series A brings in $27mm for [Aerpio Therapeutics]
Novartis BioVenture has led [Aerpio Therapeutics Inc.]’s (drug candidates for vascular and inflammation conditions) $27mm Series A venture round. Other participants included Venture Investors, Triat...
Aerpio Therapeutics completes venture financing
Aerpio Therapeutics Completes $27 Million Series A Financing
Aerpio Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that is has closed a $27 million S...
Aerpio raises $27M to develop macular edema and IBD drugs
Aerpio Therapeutics secured $27 million in a Series A financing round led by Novartis BioVentures. -More-
Financings Of The Fortnight Follows OvaScience’s Unique Route To Going Public
Plus news on recent financial activity by Stem Cells Inc., Sanofi, Avalon Ventures and Aerpio Therapeutics.
Aerpio Therapeutics Hosts Scientific Symposium on Tie2 Pathway
Aerpio Therapeutics today announced that it hosted the scientific symposium, Targeting the Tie2 Pathway for Novel Therapeutics, in Cambridge, MA, on August 19-20, 2012. The sympos...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Aerpio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel...
Aerpio Therapeutics, Inc. is a clinicalâstage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory b...
More Information about "Aerpio Therapeutics, Inc." on BioPortfolio
We have published hundreds of Aerpio Therapeutics, Inc. news stories on BioPortfolio along with dozens of Aerpio Therapeutics, Inc. Clinical Trials and PubMed Articles about Aerpio Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aerpio Therapeutics, Inc. Companies in our database. You can also find out about relevant Aerpio Therapeutics, Inc. Drugs and Medications on this site too.
